New GERD drug FEXUCLUE shows promise for heartburn relief

NCT ID NCT05660122

Completed Symptom relief Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at whether FEXUCLUE (fexuprazan) tablets can improve heartburn and acid reflux symptoms in people with erosive gastroesophageal reflux disease (GERD). Over 2,800 adults took the medication for 4 to 8 weeks and reported their symptom changes. The goal was to see if the drug helps patients feel better day-to-day.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fexuprazan Hydrochloride (FEXUCLUE tablet)
What this could lead to: If successful, this could confirm that FEXUCLUE helps relieve heartburn and acid reflux symptoms in people with erosive GERD.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It also only looks at short-term symptom improvement, not long-term healing or prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL REFLUX DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL REFLUX DISEASE

Contacts and locations

Locations

Samsung Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.